EFTA00598930Set 9
2015-10-025p4,184w
North America Equity Research
J.P.Morgan 02 October 2015
MRK/BMY
Restricted Keytruda Label as Expected; See Opdivo
Maintaining Leadership Position - ALERT
Today, the FDA approved Keytruda (PD-1) with a companion ... broaden over time as data from additional trials support (1-212)622-5676
Keytruda's efficacy in a larger patient population. Given that Opdivo is
Bloomberg JPMA SCHOTT <GO,
already ... approved in an all comer sq-NSCLC population and Keytruda has
Aditl Singhania, PhD
been granted a restricted label, we expect the uptake to be skewed towards
https://www.justice.gov/epstein/files/DataSet%209/EFTA00598930.pdf
EFTA01154025Set 9
2014-09-2120p16,048w
paradigm shift in the way the
deadly skin cancer is treated. The drug, Keytruda (pembrolizumab), was tested on more than 600 patients who had melanoma that had spread throughout their ... conducted at UCLA and is other sites in the US., Europe and Australia. Keytruda, formerly
known as MK-3475, is an antibody that targets a protein called PD-s that ... prevented the immune system from becoming active enough to attack the cancer. Keytruda, in effect, cuts the brake lines, freeing
up the immune system to attack the cancer. "This drug
https://www.justice.gov/epstein/files/DataSet%209/EFTA01154025.pdf